These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 25931519)
21. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636 [TBL] [Abstract][Full Text] [Related]
22. Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo. Xu W; Bi Y; Kong J; Zhang J; Wang B; Li K; Tian M; Pan X; Shi B; Gu J; Jiang H; Kong X; Li Z Oncotarget; 2016 Apr; 7(17):24752-65. PubMed ID: 27029073 [TBL] [Abstract][Full Text] [Related]
23. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis. Liu Z; Han L; Dong Y; Tan Y; Li Y; Zhao M; Xie H; Ju H; Wang H; Zhao Y; Zheng Q; Wang Q; Su J; Fang C; Fu S; Jiang T; Liu J; Li X; Kang C; Ren H Oncotarget; 2016 Jan; 7(4):4680-94. PubMed ID: 26717039 [TBL] [Abstract][Full Text] [Related]
24. EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. Miao H; Choi BD; Suryadevara CM; Sanchez-Perez L; Yang S; De Leon G; Sayour EJ; McLendon R; Herndon JE; Healy P; Archer GE; Bigner DD; Johnson LA; Sampson JH PLoS One; 2014; 9(4):e94281. PubMed ID: 24722266 [TBL] [Abstract][Full Text] [Related]
26. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573 [TBL] [Abstract][Full Text] [Related]
27. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246 [TBL] [Abstract][Full Text] [Related]
28. Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects. van de Water JA; Bagci-Onder T; Agarwal AS; Wakimoto H; Roovers RC; Zhu Y; Kasmieh R; Bhere D; Van Bergen en Henegouwen PM; Shah K Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16642-7. PubMed ID: 23012408 [TBL] [Abstract][Full Text] [Related]
29. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids. Nittoli T; Kelly MP; Delfino F; Rudge J; Kunz A; Markotan T; Spink J; Chen Z; Shan J; Navarro E; Tait M; Provoncha K; Giurleo J; Zhao F; Jiang X; Hylton D; Makonnen S; Hickey C; Kirshner JR; Thurston G; Papadopoulos N Bioorg Med Chem; 2018 May; 26(9):2271-2279. PubMed ID: 29605304 [TBL] [Abstract][Full Text] [Related]
30. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063 [TBL] [Abstract][Full Text] [Related]
31. Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. Takasu S; Takahashi T; Okamoto S; Oriuchi N; Nakayashiki N; Okamoto K; Muramatsu H; Hayashi T; Nakahara N; Mizuno M; Wakabayashi T; Higuchi T; Endo K; Kozaki K; Miyaishi O; Saga S; Ueda R; Yoshida J; Yoshikawa K J Neurooncol; 2003 Jul; 63(3):247-56. PubMed ID: 12892230 [TBL] [Abstract][Full Text] [Related]
32. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Zhu H; You Y; Shen Z; Shi L Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402 [TBL] [Abstract][Full Text] [Related]
34. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Iurlaro R; Waldhauer I; Planas-Rigol E; Bonfill-Teixidor E; Arias A; Nicolini V; Freimoser-Grundschober A; Cuartas I; Martínez-Moreno A; Martínez-Ricarte F; Cordero E; Cicuendez M; Casalino S; Guardia-Reyes X; Fahrni L; Pöschinger T; Steinhart V; Richard M; Briner S; Mueller J; Osl F; Sam J; Colombetti S; Bacac M; Klein C; Pineda E; Reyes-Figueroa L; Di Somma A; González J; Nuciforo P; Carles J; Vieito M; Tabernero J; Umaña P; Seoane J Mol Cancer Ther; 2022 Oct; 21(10):1499-1509. PubMed ID: 35915983 [TBL] [Abstract][Full Text] [Related]
35. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth. Karkare S; Chhipa RR; Anderson J; Liu X; Henry H; Gasilina A; Nassar N; Ghosh J; Clark JP; Kumar A; Pauletti GM; Ghosh PK; Dasgupta B Clin Cancer Res; 2014 Jan; 20(1):199-212. PubMed ID: 24170547 [TBL] [Abstract][Full Text] [Related]
36. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells. Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476 [TBL] [Abstract][Full Text] [Related]
37. The Effect of and Mechanism Underlying Autophagy in Hepatocellular Carcinoma Induced by CH12, a Monoclonal Antibody Directed Against Epidermal Growth Factor Receptor Variant III. Xu W; Song F; Wang B; Li K; Tian M; Yu M; Pan X; Shi B; Liu J; Gu J; Li Z; Jiang H Cell Physiol Biochem; 2018; 46(1):226-237. PubMed ID: 29587298 [TBL] [Abstract][Full Text] [Related]
38. Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models. Jain S; Griffith JI; Porath KA; Rathi S; Le J; Pasa TI; Decker PA; Gupta SK; Hu Z; Carlson BL; Bakken K; Burgenske DM; Feldsien TM; Lefebvre DR; Vaubel RA; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN Clin Cancer Res; 2024 Aug; 30(15):3287-3297. PubMed ID: 38743766 [TBL] [Abstract][Full Text] [Related]